Skip to main content
. 2022 Mar 12;23:211. doi: 10.1186/s13063-022-06143-w

Fig. 2.

Fig. 2

Subgroup analyses of overall survival. HR, hazard ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; D-SOX, intraperitoneal docetaxel and intravenous oxaliplatin plus taking orally S-1; DOS, intravenous docetaxel and oxaliplatin plus taking orally S-1